Gemcitabine activity in cervical cancer cell lines

Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine. Combinational cytotoxic studies using viability tests...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2001-12, Vol.48 (6), p.488-492
Main Authors: HERNANDEZ, Patricia, OLIVERA, Primitivo, DUENAS-GONZALEZ, Alfonso, PEREZ-PASTENES, Miguel A, ZARATE, Adolfo, MALDONADO, Vilma, MELENDEZ-ZAJGLA, Jorge
Format: Article
Language:English
Subjects:
Antimetabolites, Antineoplastic - pharmacology
Antineoplastic agents
Apoptosis
Biological and medical sciences
Cell Survival
Chemotherapy
Cisplatin - pharmacology
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
DNA Damage
Drug Interactions
Female
HeLa Cells
Humans
Medical sciences
Pharmacology. Drug treatments
Radiation-Sensitizing Agents - pharmacology
Tumor Cells, Cultured
Uterine Cervical Neoplasms - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gemcitabine (2',2'-difluorodeoxycytidine) is an antineoplastic agent with activity against a variety of solid tumors. To investigate its in vitro activity toward cervical cancer, we exposed six cervical cancer cell lines to gemcitabine. Combinational cytotoxic studies using viability tests and clonogenicity assays. Gemcitabine was cytostatic and cytotoxic in some of the lines at peak plasma concentrations similar to those achieved in clinical trials. Gemcitabine was also found to effectively synergize with cisplatin and showed a radiosensitizing effect in these cells. The cytotoxicity observed in sensitive cell lines was due to apoptosis, as demonstrated by DNA fragmentation assays. We recommend performing additional in vitro experimentation so that these results can be confirmed to support clinical trials of gemcitabine in cervical cancer patients both as first-line therapy and with concomitant radiation.
ISSN:0344-5704
1432-0843
DOI:10.1007/s002800100370